Scientists have tapped the immense power of the Summit supercomputer at Oak Ridge National Laboratory to comb through millions of medical journal articles to identify potential vaccines, drugs and effective measures that could suppress or stop the spread of COVID-19.
In the race to identify solutions to the COVID-19 pandemic, researchers at the Department of Energy’s Oak Ridge National Laboratory are joining the fight by applying expertise in computational science, advanced manufacturing, data science and neutron science.
As the second-leading cause of death in the United States, cancer is a public health crisis that afflicts nearly one in two people during their lifetime.
Oak Ridge National Laboratory will partner with Cincinnati Children’s Hospital Medical Center to explore ways to deploy expertise in health data science that could more quickly identify patients’ mental health risk factors and aid in suicide prevention strategies.
Researchers at the Department of Energy’s Oak Ridge National Laboratory have received five 2019 R&D 100 Awards, increasing the lab’s total to 221 since the award’s inception in 1963.
In a step toward advancing small modular nuclear reactor designs, scientists at Oak Ridge National Laboratory have run reactor simulations on ORNL supercomputer Summit with greater-than-expected computational efficiency.
Using artificial neural networks designed to emulate the inner workings of the human brain, deep-learning algorithms deftly peruse and analyze large quantities of data. Applying this technique to science problems can help unearth historically elusive solutions.
OAK RIDGE, Tenn., March 11, 2019—An international collaboration including scientists at the Department of Energy’s Oak Ridge National Laboratory solved a 50-year-old puzzle that explains why beta decays of atomic nuclei
OAK RIDGE, Tenn., March 4, 2019—A team of researchers from the Department of Energy’s Oak Ridge National Laboratory Health Data Sciences Institute have harnessed the power of artificial intelligence to better match cancer patients with clinical trials.